Brain health matters not only for individuals but also for the fate of a nation.

Brain health is about personal quality of life and, more importantly, national strategy. Today, brain health has become a core strategic track in global science and health. The United States, the European Union, Japan, Canada, and others have launched national brain science initiatives. With the full implementation of China's "One Body, Two Wings" brain initiative, the prevention and control of brain health across the entire lifespan has officially become a national strategy.

What is the core substance driving this transformation? — D3HB (D-β-hydroxybutyrate/D-3-hydroxybutyrate).

As a key ketone body naturally present in the human body, D3HB (D-β-hydroxybutyrate) has been recognized by the international scientific community as the "fourth macronutrient." Research published in top journals such as Cell, Nature, and Science has confirmed that D3HB shows tremendous potential in cognitive enhancement, mood regulation, anti-aging, and the prevention and improvement of neurodegenerative diseases such as Alzheimer's and Parkinson's. It has become a core research focus in brain health and anti-aging at world-leading institutions, including Stanford, Harvard, Cambridge, and the Buck Institute for Research on Aging.

However, the industrialization of D3HB has faced numerous challenges.

For a long time, traditional chemical synthesis of D3HB has been hampered by low chiral purity, high costs, and an inability to achieve large-scale production, making this "brain gold" difficult to make accessible to the public.

As a global pioneer in basic research and industrialization of D3HB, MedPHA, by leveraging its proprietary microbial directed synthesis technology, has become the first in the world to achieve industrial-scale production of D3HB with ultra-high optical purity. The product is homologous to endogenous D3HB in the human body, and costs have been dramatically reduced, completing the crucial leap from scientific research to consumer products and providing a vital "Chinese solution" for global brain health and anti-aging.

We are keenly aware that the value of scientific research lies in benefiting the general public.

Led by MedPHA's team of PhDs, in collaboration with Tmall Global and Shuzheng Kangxun, we have released the world's first D3HB "D-β-hydroxybutyrate" Brain Protection White Paper 2026. This white paper systematically interprets the multi-dimensional brain-protective mechanisms of D3HB, along with scientific evidence and clinical application explorations, providing a scientific basis for clinical practice, public education, and industrial R&D of D3HB. It drives the shift of brain health management from "passive treatment" to precision nutrition interventions based on physiological mechanisms with verifiable effects, offering truly implementable solutions for brain health across the entire lifespan.

At the same time, with D3HB at the core, we have created a series of D3HB oral liquid products under the SynasWell and MACHLOOM brands, covering core scenarios such as memory enhancement, cognitive improvement, emotional soothing, sleep improvement, and relief from mental fatigue. They meet the brain care needs of adolescents, adults, and the elderly throughout the lifespan, truly putting scientific concepts into practice and making China's original technology accessible to the world.

Looking to the future, Beta International relies on its professional R&D strength and product advantages to
Win the market with quality, win friendship with integrity, and win development with brand.